Immunomedics (IMMU) - moderated Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunomedics (IMMU) - moderated

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

Recommended by:

dorightbythem

idahoranch1

mokelumne river

To: weatherproof who wrote (36004)	6/17/2016 4:07:10 PM
From: weatherproof	3 Recommendations Read Replies (2) of 63282

I also wanted to point out that Dr G, as quoted in a previous post, seems to be implying that OS will be required for AA consideration. Winners - Did you find any other indication that ORR will be used in the ph2 outside of the WF comment? We need to know: 1. Endpoint for AA in the ph2 2. How many more patients are required for AA consideration in that ph2? 3. What is the benchmark for whichever endpoint they will use in the ph2? 4. How long will it approximately take to enroll the needed patients in the second stage of the ph2? 5. From last patient enrolled, how long will it take for data to mature enough to get an AA application going? 6. What is the hang-up with getting a partner on board?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next